Cargando…

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Magrolimab is a monoclonal antibody that blocks CD47, a ‘do not eat me’ signal overexpressed on tumor cells. CD47 is overexpressed in multiple myeloma (MM), which contributes to its pathogenesis. Preclinical studies have shown that CD47 blockade induces macrophage activation, resulting in eliminatio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paul, Barry, Liedtke, Michaela, Khouri, Jack, Rifkin, Robert, Gandhi, Mitul D, Kin, Andrew, Levy, Moshe Y, Silbermann, Rebecca, Cottini, Francesca, Sborov, Douglas W, Sandhu, Irwindeep, Villarreal, Lyssa, Murphy, Michael, Gu, Lin, Chen, Ann, Rajakumaraswamy, Nishanthan, Usmani, Saad Z
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2023
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10463212/ https://www.ncbi.nlm.nih.gov/pubmed/36779512 http://dx.doi.org/10.2217/fon-2022-0975

Ejemplares similares

PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
por: Paul, B., et al.
Publicado: (2022)

Managing multiple myeloma
por: Lee, Ann S., et al.
Publicado: (2021)

Management of Multiple Myeloma: A Review for General Practitioners in Oncology
por: Monteith, Bethany E., et al.
Publicado: (2023)

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma
por: Costello, Caitlin, et al.
Publicado: (2019)

P1003: RUXOLITINIB AND MAGROLIMAB INCREASES CALRETICULIN IN MYELOFIBROSIS CD34+ CELLS IN VITRO. PROOF OF CONCEPT FOR COMBINATION THERAPY.
por: Rinaldi, Ciro, et al.
Publicado: (2023)

Tolerability and Efficacy of the Anticluster of Differentiation 47 Antibody Magrolimab Combined With Azacitidine in Patients With Previously Untreated AML: Phase Ib Results
por: Daver, Naval G., et al.
Publicado: (2023)

Phase 1/2 study of carfilzomib, pomalidomide, and dexamethasone with and without daratumumab in relapsed multiple myeloma
por: Derman, Benjamin A., et al.
Publicado: (2023)

Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidine
por: Döhner, Hartmut, et al.
Publicado: (2022)

Single arm, phase two study of low-dose metronomic eribulin in metastatic breast cancer
por: Chalasani, Pavani, et al.
Publicado: (2021)

Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE
por: San-Miguel, Jesus, et al.
Publicado: (2022)

Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma
por: Mu, Song, et al.
Publicado: (2015)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Short arm cast is as effective as long arm cast in maintaining distal radius fracture reduction: Results of the SLA-VER noninferiority trial
por: Dib, Giovanni, et al.
Publicado: (2022)

Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism
por: Huang, Yung-Hsing, et al.
Publicado: (2021)

Burosumab Improved Histomorphometric Measures of Osteomalacia in Adults with X‐Linked Hypophosphatemia: A Phase 3, Single‐Arm, International Trial
por: Insogna, Karl L, et al.
Publicado: (2019)

25487 Timing and strength of hand grasp that are affected by abnormal coupling between arm muscles following stroke: A pilot study
por: Kim, Dongwon, et al.
Publicado: (2021)

A phase I first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone in patients with progressive multiple myeloma
por: Metselaar, Josbert, et al.
Publicado: (2023)

Myeloma bone disease: Pathophysiology and management
por: Silbermann, Rebecca, et al.
Publicado: (2013)

Infliximab biosimilar CT-P13 therapy in patients with Takayasu arteritis with low dose of glucocorticoids: a prospective single-arm study
por: Park, Eun Hye, et al.
Publicado: (2018)

Volume Matters in Ultrasound-Guided Perineural Dextrose Injection for Carpal Tunnel Syndrome: A Randomized, Double-Blinded, Three-Arm Trial
por: Lin, Meng-Ting, et al.
Publicado: (2020)

PB2021: PHASE 2 STUDY OF ORAL DECITABINE/CEDAZURIDINE IN COMBINATION WITH MAGROLIMAB FOR PREVIOUSLY UNTREATED SUBJECTS WITH INTERMEDIATE TO VERY HIGH-RISK MYELODYSPLASTIC SYNDROMES (MDS)
por: Zeidan, Amer M., et al.
Publicado: (2023)

A randomized, phase II, three-arm study of two schedules of ixabepilone or paclitaxel plus bevacizumab as first-line therapy for metastatic breast cancer
por: Rugo, Hope S., et al.
Publicado: (2013)

Functional outcomes and quality of life after a 6-month early intervention program for oral cancer survivors: a single-arm clinical trial
por: Chen, Yueh-Hsia, et al.
Publicado: (2018)

Advanced Imaging of Multiple Myeloma Bone Disease
por: Hansford, Barry G., et al.
Publicado: (2018)

Optimal C-arm angulation during transcatheter aortic valve replacement: Accuracy of a rotational C-arm computed tomography based three dimensional heart model
por: Veulemans, Verena, et al.
Publicado: (2016)

Prise en charge du myélome multiple
por: Lee, Ann S., et al.
Publicado: (2021)

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study
por: Kuemmel, Sherko, et al.
Publicado: (2021)

Pyrotinib combined with trastuzumab and chemotherapy for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer: a single-arm exploratory phase II trial
por: Xie, Xiao-Feng, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin (Duomeisu(®)) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
por: Jiang, Hanfang, et al.
Publicado: (2023)

P699: MAGROLIMAB ALTERS THE TUMOR MICROENVIRONMENT TO IMPROVE BONE MARROW FUNCTIONS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR-MDS)
por: Johnson, Lisa, et al.
Publicado: (2023)

Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
por: Chung, David J., et al.
Publicado: (2023)

OncoVee™-MiniPDX-guided anticancer treatment for HER2-negative intermediate-advanced gastric cancer patients: a single-arm, open-label phase I clinical study
por: Zhang, Baonan, et al.
Publicado: (2023)

A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019)

ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: rationale and design
por: Fulcher, Gregory R., et al.
Publicado: (2021)

Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials
por: Kanapuru, Bindu, et al.
Publicado: (2022)

Depth of response and response kinetics of isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma
por: Martin, Thomas, et al.
Publicado: (2022)

Racial and ethnic differences in clonal hematopoiesis, tumor markers, and outcomes of patients with multiple myeloma
por: Peres, Lauren C., et al.
Publicado: (2022)

Clinical characteristics and outcomes of IgD myeloma: experience across UK national trials
por: Agbuduwe, Charles, et al.
Publicado: (2022)

More intensive therapy has a better effect for frail parents with multiple myeloma
por: DuMontier, Clark, et al.
Publicado: (2023)

Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma
por: Lee, Dae Hyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_mp7k0fqp5tb81m3e7rbf4lc4h0